ArticleCancer medicine2026
Identification and Validation of cGAS-STING Pathway-Associated Predictive and Therapeutic Models for Esophageal Squamous Cell Cancer Patients via Artificial Intelligence and Multi-Omics.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEsophageal squamous cell cancer (ESCC) is a malignancy derived from the Esophagus, and dysregulation of the cGAS-STING pathway contributes to ESCC progression.
methodESCC bulk-seq dataset GSE38129 was acquired from GEO database and then underwent Limma and WGCNA analysis for the identification of shared DEGs, which were intersected with cGAS-STING pathway gene list and underwent Cox regression analysis for recognized cGAS-STING associated prognostic indicators. Next, Consensus clustering and machine learning combinations (Lasso + SurvivalSVM) were utilized for cGAS-STING associated ESCC molecular subgroups and prognostic model construction in TCGA-ESCC cohorts, and prognostic performance was validated in GSE53662. Besides, hub prognostic variables were acquired from Lasso-Cox regression, and their molecular and immune features were estimated via multiple bioinformatic approaches at TCGA-ESCC cohort. In addition, heterogeneity of hub genes at single-cell level for ESCC patients was also indicated in GSE188900 in spatial and temporal manners. Furthermore, Drug sensitivity and molecular docking analysis were performed for identification of optimal therapeutic agents targeting hub genes. Indeed, in vitro assays have been performed to assess the oncogenic potential of hub genes and efficacy of optimal therapeutic agents. Furthermore, implications of hub genes with cGAS-STING pathway were estimated in single-cell artificial intelligence (AI) driven-virtual cell and bulk assays.
resultsBy utilizing integrative AI and multi-omic pipelines, we proved that the cGAS-STING pathway can guide subgroup stratification and prognostic model construction for ESCC patients. PRKDC and SLC25A13 can be considered hub genes associated with ESCC pathogenesis and regulation of the cGAS-STING pathway. BX-912 and Navitoclax can be considered drug screening strategies for the treatment of ESCC patients by targeting PRKDC and SLC25A13.
conclusioncGAS-STING pathway can guide risk stratification and can be considered as a therapeutic target for ESCC patients, which provides novel insights into precision and personalized medicine for ESCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.